NCT02477670View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 21, 2017

Study Completion Date

July 21, 2017

Conditions
Schizophrenia
Interventions
DRUG

AVP-786

DRUG

Placebo

Trial Locations (17)

Unknown

Cerritos

Garden Grove

National City

Oakland

San Diego

Washington D.C.

Orlando

Atlanta

Augusta

Chicago

Boston

Worcester

Grand Rapids

Marlton

Jamaica

New York

Rochester

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY